References
- Singer M, Deutschman CS, Seymour CW, et al The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:801-10.
- Kaukonen K, Bailey M, Suzuki S, et al Mortality Related to Severe Sepsis and Septic Shock Among Critically Ill Patients in Australia and New Zealand, 2000-2012. JAMA. 2014;311:1308-16.
- Bone RC, Balk RA, Cerra FB, et al American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 1992;20:864-74.
- Ventetuolo CE, Levy MM. Sepsis: a clinical update. Clin J Am Soc Nephrol. 2008;3:571-7.
- Venkata C, Kashyap R, Farmer JC, et al Thrombocytopenia in adult patients with sepsis: incidence, risk factors, and its association with clinical outcome. J Intensive Care. 2013;1:9.
- Daly ME. Determinants of platelet count in humans. Haematol. 2011;96:10-3.
- Drews RE, Weinberger SE. Thrombocytopenic disorders in critically ill patients. Am J Respir Crit Care Med. 2000;162:347–51.
- Stephan F, Hollande J, Richard O, et al Thrombocytopenia in a surgical ICU. Chest. 1999;115:1363–70.
- Bonfiglio MF, Traeger SM, Kier KL, et al Thrombocytopenia in intensive care patients: a comprehensive analysis of risk factors in 314 patients. Ann Pharmacother. 1995;29:835–42.
- Cawley MJ, Witbrodt ET, Boyce EG, et al Potential risk factors associated with thrombocytopenia in a surgical intensive care unit. Pharmacotherapy. 1999;19:108–13.
- Shalansky SJ, Verma AK, Levine M, et al Risk markers for thrombocytopenia in critically ill patients: a prospective analysis. Pharmacotherapy. 2002;22:803–13.
- Abraham E, Anzueto A, Gutierrez G, et al Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. NORASEPT II study group. Lancet. 1998;351:929–33.
- Cohen J, Carlet J. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International sepsis trial study group. Crit Care Med. 1996;24:1431–40.
- Munford RS, Sufredini AF. Sepsis, Severe sepsis, and septic shock. In Mandell GL, Bennet JE, Dolin R. (Eds.) Mandell, Douglas, and Bennet’s Principles and Practice of Infectious Diseases. Seventh Edition. Philadelphia: Churchill Livingstone. 2010, pp. 987-1010.
- Lambert MP, Gernsheimer TB. Clinical updates in adult immune thrombocytopenia. Blood. 2017;129:2829–35.
- Gonzalez-Porras JR, Bastida JM. Eltrombopag in immune thrombocytopenia: efficacy review and update on drug safety. Ther Adv Drug Saf. 2018;9:263–85.
- Kim TO, Despotovic J, Lambert MP. Eltrombopag for use in children with immune thrombocytopenia. Blood Adv. 2018;2:454–61.
- Bussel JB, Cheng G, Saleh MN, et al Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med. 2007;357:2237-47.
- Barrios NJ, Humbert JR, McNeil J. Treatment of acute idiopathic thrombocytopenic purpura with high-dose methylprednisolone and immunoglobulin. Acta Haematol. 1993;89:6-9.
- Cheng G. Eltrombopag, a thrombopoietin- receptor agonist in the treatment of adult chronic immune thrombocytopenia: a review of the efficacy and safety profile. Ther Adv Hematol. 2012;3:155-64.
- Saleh MN, Bussel JB, Cheng G, et al Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121:537–45.
- McMillan R, Wang L, Tomer A, et al Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103:1364–9.
- Nurden AT, Viallard JF, Nurden P. New-generation drugs that stimulate platelet production in chronic immune thrombocytopenic purpura. Lancet. 2009;373:1562–69.
- Ali N, Auerbach HE. New-onset acute thrombocytopenia in hospitalized patients: pathophysiology and diagnostic approach. J Community Hosp Intern Med Perspect. 2017;7:157–67.
- Kaushansky K. Thrombopoiesis. Semin Hematol. 2015;52:4– 11.
- Mason KD, Carpinelli MR, Fletcher JI, et al Programmed anuclear cell death delimits platelet life span. Cell. 2007;128:1173–86.
- Akca S, Haji-Michael P, de Mendonça A, et al Time course of platelet counts in critically ill patients. Crit Care Med. 2002;30:753–6.
- Cawley MJ, Witbrodt ET, Boyce EG, et al Potential risk factors associated with thrombocytopenia in a surgical intensive care unit. Pharmacotherapy. 1999;19:108–13.
- Shalansky SJ, Verma AK, Levine M, et al Risk markers for thrombocytopenia in critically ill patients: a prospective analysis. Pharmacotherapy. 2002;22:803–13.
- Sharma B, Sharma M, Majumder M, et al Thrombocytopenia in septic shock patients–a prospective observational study of incidence, risk factors and correlation with clinical outcome. Anaesth Intensive Care. 2007;35:874–80.
- Dewite A, Lepreux S, Villeneuve J, et al Blood platelets and sepsis pathophysiology: A new therapeutic prospect in critical ill patients? Ann. Intensive Care. 2017;7:115.
- Riedemann NC, Guo RF, Ward PA. The enigma of sepsis. J Clin Investig. 2003;112:460–7.
- Aziz M, Jacob A, Yang WL, et al Current trends in inflammatory and immunomodulatory mediators in sepsis. J Leukoc Biol. 2013;93:329–42.
- Yang D, Han Z, Oppenheim JJ. Alarmins and immunity. Immunol Rev. 2017;280:41–56.
- Xiao W, Mindrinos MN, Seok J, et al A genomic storm in critically injured humans. J Exp Med. 2011;208:2581–90.
- Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost. 2011;105:S13–33.
- Garraud O, Hamzeh-Cognasse H, Pozzetto B, et al Bench-to-bedside review: platelets and active immune functions-new clues for immunopathology? Crit Care. 2013;17:236.
- Nurden AT. The biology of the platelet with special reference to inflam-mation, wound healing and immunity. Front Biosci (Landmark Ed). 2018;23:726–51.
- Thiolliere F, Serre-Sapin AF, Reignier J, et al Epidemiology and outcome of thrombocytopenic patients in the intensive care unit: results of a prospective multicenter study. Intensive Care Med. 2013;39:1460–8.
- Lim SY, Jeon EJ, Kim HJ, et al The incidence, causes, and prognostic significance of new-onset thrombocytopenia in intensive care units: a prospective cohort study in a Korean hospital. J Korean Med Sci. 2012;27:1418–23.
- Antier N, Quenot JP, Doise JM, et al Mecha-nisms and etiologies of thrombocytopenia in the intensive care unit: impact of extensive investigations. Ann Intensive Care. 2014;4:24.
- Francois B, Trimoreau F, Vignon P, et al Thrombocytopenia in the sepsis syndrome: role of hemophagocytosis and macrophage colony-stimulating factor. Am J Med. 1997;103:114–20.
- Stephan F, Thioliere B, Verdy E, et al Role of hemophagocytic histiocytosis in the etiology of thrombocytopenia in patients with sepsis syndrome or septic shock. Clin Infect Dis. 1997;25:1159–64.
- Ghosh TK, Khan N, Malik A. Platelet auto-antibodies in septicaemic patients. Indian J Pathol Microbiol. 1999;42:31-5.
- Graham SM, Liles WC. Platelets in sepsis: beyond hemostasis. Blood. 2016;127:2947-9.
- Herter JM, Rossaint J, Zarbock A. Platelets in inflammation and immunity. J Thromb Haemost. 2014;12:1764-75.
- Semple JW, Italiano JE Jr, Freedman J. Platelets and the immune continuum. Nat Rev Immunol. 2011;11:264-74.
- GlaxoSmithKline. Promacta (eltrombopag tablets): US prescribing information. 2011. Available at htp://us.gsk.com/products/assets/us_promacta.pdf [accessed 23 January 2019].
- Erhardt J, Erickson-Miller CL, Tapley P. SB 497115-GR, a low molecular weight TPOR agonist, does not induce platelet activation or enhance agonist-induced platelet aggregation in vitro. Blood. 2004;104:59b.